Boston continues to be home to numerous tech innovators dedicated to improving human health. Several biology and medical technology companies finished November with hefty funding rounds to advance their solutions. Learn more about how these businesses are growing.
Top Boston Tech Funding Rounds, November 2023
- Elucid
- Ascidian Therapeutics
- Eleos Health
- Stellaromics
- OfferFit
#3. (tied) $25 million, November 14
Marketing tech company OfferFit uses AI to automate campaign experimentation, helping lifecycle marketers optimize their campaigns faster. The company secured $25 million in a round led by Menlo Ventures. It wants to scale its operations and fuel product development with the fresh capital.
#3. (tied) $25 million, November 2
Stellaromics is developing spatial technology that could accelerate the development of drug treatments for autoimmune diseases, cancer, neuropsychiatric disorders and infectious diseases. The company raised Series A financing from investors including Plaisance Capital Management to grow its team and invest in product innovation and commercialization.
#2. (tied) $40 million, November 8
Eleos Health leverages AI to offer interpret, analyze and document behavioral health conversations, lightening the administrative loads on providers. The company raised $40 million in new funding to enhance its solutions for group therapy, compliance automation, case management, concurrent documentation and value-based care support. The raise will also help it hire new talent and fuel strategic partnerships.
#2. (tied) $40 million, November 8
Biotech company Ascidian Therapeutics works to treat human diseases by editing exons at the RNA level to enable the precise, post-transcriptional editing of genes. The company announced a Series A extension round from Apple Tree Partners that will go toward advancing the programs in its pipeline.
#1. $80 million, November 9
Medtech company Elucid works to offer physicians AI-powered imaging analysis software for assessing cardiovascular disease. The company pulled in a round of Series C funding to expand its commercialization efforts. The additional $80 million from lead investor Elevage Medical Technologies brings Elucid’s total funding to $121 million.
